[A peptide vaccine containing an epitope of human tumor-associated KSA antigen (Ep-CAM) conjugated with keyhole limpet hemocyanin (KLH), with potential antineoplastic activity. KSA antigen, a type-I transmembrane glycoprotein and a cellular adhesion molecule with a molecular mass of 40 kDa, is overexpressed on the majority of epithelia tumor cells. KSA antigen is conjugated with KLH, an immunostimulant and a hapten carrier, to enhance immune recognition. Vaccination with KSA-KLH may result in the production of antibodies as well as elicit a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the KSA antigen. ( NCI )] (UMLS (NCI) C0796598) KSA-KLH Conjugate Vaccine =Pharmacologic Substance; Immunologic Factor ;